The BTF welcomes the provisional findings of the Competition and Markets Authority (CMA) which has found that Concordia overcharged the NHS by millions for the supply of Liothyronine. There are many thyroid patients who have told us that this medicine makes a huge difference to their lives and the enormous price rise has caused significant confusion and distress. We look forward to the CMA's final decision and very much hope it will take account of patients’ clinical needs and lead to an improvement in care. 

The information on the BTF website is widely used by people from all over the world. In order to make our resources more accessible to speakers of other languages we have translated our four most popular information guides into Arabic, Polish and Urdu. If you find these documents useful or would like to be able to access other BTF information in these or other languages please email

NICE (the National Institute for Health and Care Excellence) has been asked by the Department of Health in England to develop a clinical guideline on thyroid disease for England. This guideline will be used to develop the NICE quality standard for the diagnosis and management of thyroid conditions and the recommendations will be included in the NICE Pathway for thyroid disease.